Vial

INDIVIDUAL TEST 987

pTau-181 (phospho Tau 181)

Indication

Alzheimer's disease, memory examination 

Method

SIMOA (single molecule array), tested in EDTA-plasma. 

Result

The result is reported as ng/L.  

Interpretation

Plasma pTau-181 ≥ 4.0 pg/ml support further investigations when Alzheimer's disease is suspected. The cut-off represents 99th-percentile of 150 healthy individuals. 

The result should be combined with other investigations as well as clinical symptoms for the final diagnosis. The method is not yet validated for clinical routine diagnostic purpose. 

References 

  • Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-344.
  • Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433.  
  • Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology, and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26(3):379-386.   
  • Liu, Huei-Chun et al. Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dementia and geriatric cognitive disorders. Extra vol. 10,1 46-55. 26 Mar. 2020, 
  • Elisabeth H T et al., Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021 Sep;20(9):739-752. 
  • Antoinette O’Connor et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. Molecular Psychiatry volume 26, pages5967–5976 (2021) 

More information

Learn more about sampling.
> Read more

Download request forms

Neurology

Can't find what you're looking for? We are here to help

Vial

ENSKILD ANALYS 987

pTau-181 (fosfo Tau 181)

Indikation

Alzheimers sjukdom, minnesutredning. 

Metod

SIMOA (single molecule array), analys utförs i EDTA-plasma.  

Svar

Resultat rapporteras som ng/L.  

Tolkning

Plasma pTau-181 ≥ 4.0 pg/ml motiverar vidare utredning vid misstanke om Alzheimers sjukdom. Referensvärdet representerar 99:e percentilen av 150 friska individer.  

Diagnosen baseras även på kliniska symtom och andra undersökningsfynd. Metoden är ännu inte validerad för klinisk rutindiagnostik. 

Referenser 

  • Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-344.
  • Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433.  
  • Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology, and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26(3):379-386.   
  • Liu, Huei-Chun et al. Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dementia and geriatric cognitive disorders. Extra vol. 10,1 46-55. 26 Mar. 2020, 
  • Elisabeth H T et al., Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021 Sep;20(9):739-752. 
  • Antoinette O’Connor et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. Molecular Psychiatry volume 26, pages5967–5976 (2021) 

Mer information

Mer information om provtagning.
> Läs mer

Ladda ner remiss

Neurologi

Hittar du inte vad du söker? Vi kan hjälpa till